Medicine
Venous Thromboembolism Prophylaxis in Ambulatory Cancer Patients
Quick fact
In some cancer types like pancreatic or gastric cancer, the risk of blood clots can be over 10% in the first few months of chemotherapy, yet they are lower for many other cancers.
Why this is interesting
Some cancer patients on chemotherapy develop dangerous blood clots, but giving all of them blood thinners can cause serious bleeding. How do doctors decide who truly needs prevention?
Read the full explanation
Understanding Venous Thromboembolism Prophylaxis in Ambulatory Cancer Patients
Cancer itself and certain treatments like chemotherapy increase the tendency of blood to clot. This leads to venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism. In ambulatory patients—those not hospitalized—the risk varies widely depending on cancer type, stage, and treatment. To avoid blanket anticoagulation, doctors use a tool called the Khorana score to predict risk. This score considers factors like cancer site, blood cell counts, and body mass index. Patients with a higher score are candidates for preventive blood thinners, while those with low scores are not. The idea is to target the highest‑risk individuals to prevent clots without exposing many low‑risk patients to bleeding complications.
A deeper explanation
Why does cancer increase clotting risk? Cancer cells release pro‑coagulant factors, and the body's inflammatory response promotes a hypercoagulable state. Chemotherapy can further damage the inner lining of blood vessels (endothelium), triggering clot formation. VTE is not just dangerous in itself; it can delay cancer treatment and worsen prognosis. The Khorana score, published in 2008, uses clinical and lab variables to categorize patients into low, intermediate, and high risk. Randomized trials like CASSINI and AVERT showed that in high‑risk patients (Khorana ≥2), giving a direct oral anticoagulant (rivaroxaban or apixaban) significantly reduces VTE episodes, but it also increases bleeding risk. Therefore, prophylaxis is recommended only for those with a Khorana score ≥2 and low bleeding risk, while others receive only education and careful surveillance. This precision approach balances benefit and harm, reflecting modern evidence‑based medicine.